10 CSR contributions 0.2 $ MN Revenue $151.5MN Fixed assets $147.8MN Profit after tax (PAT) $1.2MN In 2023, we entered our Silver Jubilee year, surpassing the vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various stages of clinical development. At a glance
RkJQdWJsaXNoZXIy MTIwMDc4NQ==